Search Results
Your search for ,WHo matches 20407 pages
Showing 1901 - 1950Expert Point of View: Neha Vapiwala, MD, FASTRO
Discussant of the PACE-B abstract, Neha Vapiwala, MD, FASTRO, acknowledged the impressive efforts of PACE investigators to elucidate the various treatment options for patients with localized prostate cancer—a challenging task because of the frequent absence of clear evidence. Dr. Vapiwala is...
PACE Trials Support Stereotactic Body Radiotherapy for Some Patients With Localized Prostate Cancer
Prostate cancer treatment just got a major boost from the PACE trials, which may have established a new standard of care in low- and favorable intermediate-risk disease, according to data presented at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 The results of the phase ...
Intraductal Papillary Mucinous Neoplasms: Risk of Pancreatic Cancer
In a retrospective cohort study reported in JAMA Network Open, de la Fuente et al found that the risk of pancreatic cancer in patients with Fukuoka criteria–negative intraductal papillary mucinous neoplasms (F-N IPMNs) did not differ from that in patients without IPMNs. In addition, the small...
Expert Point of View: Marina C. Garassino, MD
“CheckMate 77T shows very promising results to support the use of perioperative nivolumab in resectable NSCLC,” said formal discussant Marina C. Garassino, MD, of the University of Chicago. “In particular, the trial demonstrated that patients could achieve incredible disease control rates. These...
Perioperative Nivolumab Plus Chemotherapy Improves Event-Free Survival in Resectable Non–Small Cell Lung Cancer
A perioperative regimen of neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab achieved a statistically significant and clinically meaningful improvement in event-free survival compared with neoadjuvant chemotherapy plus placebo followed by surgery and adjuvant...
FDA Approves Toripalimab-tpzi for Nasopharyngeal Carcinoma
On October 27, the U.S. Food and Drug Administration (FDA) approved toripalimab-tpzi (Loqtorz) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma. The FDA also approved toripalimab-tpzi as a single agent for...
Two New Studies Using CancerLinQ Data
Two new studies—presented by Drumheller et al and Vento et al at the 2023 ASCO Quality Care Symposium—utilized data from ASCO’s CancerLinQ® database (Abstracts 418 and 532). One study revealed deficiencies in biomarker testing and tracking in electronic health records, and the other analyzed...
Datopotamab Deruxtecan May Improve Progression-Free Survival in Patients With Metastatic NSCLC
The TROP-2–directed antibody-drug conjugate datopotamab deruxtecan may significantly improve progression-free survival in patients with metastatic non–small cell lung cancer (NSCLC), especially in patients with non–squamous cell tumors, according to new findings simultaneously published by Ahn et...
Sequential CD19- and CD22-Directed CAR T-Cell Therapy in Pediatric B-Cell ALL
In a Chinese single-center phase II study reported in The Lancet Oncology, Pan et al found that sequential CD19- and CD22-directed chimeric antigen receptor (CAR) T-cell therapy was active in pediatric patients with refractory or relapsed B-cell acute lymphocytic leukemia (ALL). Study Details In...
Enzalutamide With or Without Leuprolide and Leuprolide Alone in Biochemically Recurrent Prostate Cancer
In the phase III EMBARK trial reported in The New England Journal of Medicine, Stephen J. Freedland, MD, and colleagues found that enzalutamide/leuprolide and enzalutamide alone improved metastasis-free survival vs leuprolide alone in patients with high-risk biochemical recurrence of prostate...
Pembrolizumab Plus Lenvatinib as Second- and Third-Line Treatments of Pleural Mesothelioma
In a Dutch single-institution phase II trial (PEMMELA) reported in The Lancet Oncology, Douma et al found that the combination of pembrolizumab and lenvatinib showed activity as second- and third-line treatments of patients with pleural mesothelioma. Study Details A total of 38 evaluable patients...
PFAS Exposure May Increase Risk of Thyroid Cancer
Researchers may have discovered a link between certain per- and polyfluoroalkyl substances (PFAS)—also referred to as "forever chemicals"—and an increased risk of thyroid cancer, according to a recent study published by van Gerwen et al in eBioMedicine. Background PFAS are a large, complex group of ...
Early Triple-Negative Breast Cancer
This is Part 3 of Updates in Early-Stage Breast Cancer,, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Erika Hamilton, Michael Danso, and Komal Jhaveri discuss the management of early triple-negative breast cancer. The...
Early Hormone Receptor–Positive/HER2-Negative Breast Cancer
This is Part 1 of Updates in Early-Stage Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Erika Hamilton, Michael Danso, and Komal Jhaveri discuss the management of early hormone receptor–positive/HER2-negative...
Text Message–Based Prescreening Could Benefit Patients Receiving Immunotherapy
Researchers have found that a text message–based program in combination with routine laboratory testing could safely accelerate patients to treatment with immune checkpoint inhibitors, eliminate the need for in-person assessments with their physicians, and save them about 1.5 hours in total wait...
Yoga-Based Supportive Care May Prevent Treatment-Related Complications in Patients With Head and Neck Cancer
Yoga-based supportive care may help alleviate the negative side effects of radiation treatment, decrease the use of feeding tube placements, and reduce emergency department visits in patients with head and neck cancer, especially when family caregivers participate, according to new findings...
Mind-Body Fitness Classes May Reduce Unplanned Hospitalizations, Urgent Care Visits During Cancer Care
Participation in virtual mind-body fitness classes may be effective at reducing hospitalizations, urgent care visits, and the length of hospital stays among patients with cancer by about 50%, according to new findings presented by Mao et al at the 2023 ASCO Quality Care Symposium (Abstract 473)....
Perioperative Chemotherapy and Pembrolizumab in Locally Advanced Resectable Gastric and Gastroesophageal Junction Adenocarcinomas
In a phase II trial reported in JAMA Oncology, Manji et al found that perioperative chemotherapy and pembrolizumab showed activity in locally advanced resectable gastric and gastroesophageal junction adenocarcinoma. Study Details Thirty-four evaluable patients were enrolled in the...
Primary Care Intervention to Improve Follow-up of Overdue Abnormal Cancer Screening Test Results
In a study reported in JAMA, Atlas et al found that a primary care intervention including electronic health record (EHR) reminders and patient outreach with or without patient navigation improved timeliness of follow-up of overdue abnormal cancer screening test results. Study Details The open-label ...
Overcoming the Challenges of Treating Adolescents and Young Adults With Cancer Living in Rural Communities
It is widely acknowledged that patients with cancer living in rural areas of the United States face limited access to medical and oncology providers, often have to travel long distances to receive care, and experience obstacles in clinical trial participation—all of which affect quality of care and ...
Diagnosis of Cardiovascular Disease and Risk of Subsequent Incident Cancer Diagnosis
In a retrospective cohort study reported in JACC: CardioOncology, Caitlin F. Bell, MD, of the Division of Cardiovascular Medicine, Stanford University School of Medicine, and colleagues found that persons with a diagnosis of cardiovascular disease (CVD) were more likely to have a subsequent...
Comparing Two Radiation Therapy Techniques for Locally Advanced NSCLC: Focus on Toxicity
Intensity-modulated radiation therapy (IMRT) reduced the risk of toxicity to the lungs and radiation exposure to the heart vs three-dimensional conformal radiotherapy (3D-CRT) for the treatment of locally advanced non–small cell lung cancer (NSCLC), according to a planned long-term prospective...
Role of TROP-2–Directed Antibody-Drug Conjugates With Immune Checkpoint Inhibitors in Advanced NSCLC
Early-phase trials demonstrate the potential for TROP-2–directed antibody-drug conjugates to enhance the response to immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC) without actionable genomic alterations, several investigators reported at the International...
University of Arizona Welcomes Thoracic Surgeon Praveen Sridhar, MD
The University of Arizona College of Medicine–Tucson Department of Surgery is pleased to welcome Praveen Sridhar, MD, as Clinical Associate Professor in the Department of Surgery’s Division of Cardiothoracic Surgery. Dr. Sridhar, who is particularly interested in thoracic oncology and minimally...
From Humble Beginnings, Elisabete Weiderpass, MD, MSc, PhD, Distinguishes Herself as First Woman to Head the IARC
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Elisabete Weiderpass, MD, MSc, PhD, a Brazilian cancer researcher who is a naturalized Swedish and Finnish citizen. She is an expert in cancer epidemiology and cancer prevention. In...
HERTHENA-Lung01: Antitumor Activity Shown With HER3-DXd in EGFR-Mutated NSCLC
The treatment of patients with epidermal growth factor receptor (EGFR)-mutated lung cancer that progresses on EGFR-targeted tyrosine kinase inhibitors has been challenging. In the phase II HERTHENA-Lung01 trial, the topoisomerase-1 HER3-targeting antibody-drug conjugate patritumab deruxtecan...
Patient Education Materials on Breast Cancer May Be Difficult to Access
Investigators have discovered that reliable educational materials about breast cancer surgery may be difficult to access and are often presented at much higher reading levels than recommended, according to the findings of two new studies presented by Brennan et al and Satarasinghe et al at the...
Novel Strategies for Eliminating Dormant Tumor Cells in Breast Cancer Survivors
Researchers have discovered that it may be possible to detect and treat dormant tumor cells in breast cancer survivors, according to new findings presented by DeMichele et al at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract 244MO). The results may have offered a...
PSMAfore: Lutetium Lu-177 Vipivotide Tetraxetan in Metastatic Prostate Cancer
Data from the phase III PSMAfore trial were presented during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA13). Results showed that the trial of lutetium Lu-177 vipivotide tetraxetan met its primary endpoint, with a clinically meaningful and ...
Major Pathologic Response to Neoadjuvant Pembrolizumab in Advanced Melanoma Trial Exceeds 50%
In exploratory analyses of results from the SWOG S1801 trial in patients with stage III to IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant pembrolizumab. These and other results of...
Germline Cancer-Predisposing Variants and Increased Risk of Late Mortality From Subsequent Malignant Neoplasms in Long-Term Childhood Cancer Survivors
In an analysis from the St. Jude Lifetime Cohort (SJLIFE) and Childhood Cancer Survivor Study (CCSS) reported in The Lancet Oncology, Chen et al found that among long-term survivors of childhood cancers, carriers of germline cancer-predisposing variants were at an increased risk of late mortality...
Induction Chemotherapy and Subsequent Chemoradiation May Improve Survival and Recurrence Rates in Patients With Cervical Cancer
Researchers have found that a short course of induction chemotherapy prior to chemoradiation may be effective at reducing the rate of relapse and mortality among patients with locally advanced cervical cancer, according to new preliminary findings presented by McCormack et al at the European...
Nivolumab Plus Gemcitabine and Cisplatin May Improve Survival in Patients With Metastatic Urothelial Carcinoma
Researchers have found that nivolumab in combination with a chemotherapy regimen may improve the rate of survival in patients with metastatic urothelial carcinoma, according to new findings simultaneously published by van der Heijden et al in The New England Journal of Medicine and presented at the ...
Cabozantinib for Pretreated Patients With Advanced Neuroendocrine Tumors: CABINET Trial
The Alliance for Clinical Trials in Oncology announced detailed results from CABINET (Alliance A021602), a phase III pivotal trial evaluating cabozantinib compared with placebo in two cohorts of previously treated patients with neuroendocrine tumors. The data were presented by Chan et al at the...
Erdafitinib Demonstrates Improved Responses in FGFR-Altered Advanced Urothelial Carcinoma
Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib improved responses and overall survival compared to standard chemotherapy for patients with advanced or metastatic urothelial carcinoma with FGFR alterations. Results from the phase III THOR trial, led by...
ESMO 2023: New Data in Skin Cancers
At the European Society for Medical Oncology (ESMO) Congress 2023, new findings are being presented in cutaneous squamous cell carcinoma, late-stage melanoma, and refractory melanoma brain metastases. Presurgical Immunotherapy in Advanced Operable Cutaneous Squamous Cell Carcinoma Patients with...
FDA Expands Pediatric Indication for Entrectinib and Approves New Pellet Formulation
On October 20, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the small-molecule tyrosine kinase inhibitor entrectinib (Rozlytrek) for pediatric patients aged 1 month and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion...
EVEREST Trial: Adjuvant Everolimus for High-Risk Clear Cell Renal Cell Carcinoma
A secondary analysis from the phase III SWOG S0931 EVEREST trial found patients with clear cell renal cell carcinoma at very high risk of recurrence after nephrectomy who received adjuvant everolimus had a statistically significant improvement in recurrence-free survival compared to patients who...
Pre- and Postsurgical Immunotherapy Improves Outcomes for Patients With Resectable Early-Stage NSCLC
Compared with neoadjuvant chemotherapy alone, adding perioperative immunotherapy—given before and after surgery—significantly improved event-free survival in patients with resectable early-stage non–small cell lung cancer (NSCLC). Results from the phase III CheckMate 77T study were presented at the ...
Is Idecabtagene Vicleucel Effective in Patients With Multiple Myeloma, Regardless of Race?
The chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel may offer an overall survival benefit in patients with multiple myeloma, regardless of their race or ethnicity, according to a novel study published by Peres et al in Blood Advances. Background Multiple myeloma—a cancer of...
Patients and Survivors of Cancer May Be Impacted by U.S. Drug Shortages
The drug shortage crisis in the United States may continue to impact the care of 10% of patients and survivors of cancer, according to a new survey from the American Cancer Society Cancer Action Network (ACS CAN). Survey Findings In the new survey, researchers asked 1,222 patients and survivors of...
Efficacy of Radiotherapy in Rhabdomyosarcoma
In an analysis of data from two clinical trials and a soft-tissue sarcoma registry reported in the Journal of Clinical Oncology, Koscielniak et al identified which patients aged ≤ 21 years with localized rhabdomyosarcoma appeared to derive benefit from radiation therapy. Study Details The study...
Combination of Ceralasertib and Durvalumab Shows Activity in Phase II Trial of Advanced NSCLC
The combination of the ATR inhibitor ceralasertib and the immune checkpoint inhibitor durvalumab has demonstrated notable survival rates and clinical benefits among patients who have advanced non–small cell lung cancer (NSCLC) with RAS mutations, according to data presented at the International...
MRI Scans Could Predict Postradiation Urinary Side Effects in Patients With Prostate Cancer
Researchers have discovered that patients with longer prostatic urethras may have an increased risk of experiencing moderate and chronic urinary side effects after receiving radiation for prostate cancer, according to a recent study published by Lee et al in Academic Radiology. The new findings...
CNS Prophylaxis With High-Dose Methotrexate in High-Risk Aggressive B-Cell Lymphoma
In a retrospective study reported in the Journal of Clinical Oncology, Lewis et al found that prophylactic high-dose methotrexate did not appear to offer a clinically meaningful reduction in risk of central nervous system (CNS) disease progression in patients with high-risk aggressive B-cell...
Air Pollution and Breast Cancer Risk: Residential and Workplace Exposure
Women living and working in places with higher levels of fine particle air pollution are more likely to get breast cancer than those living and working in less polluted areas. Results of a study looking at the effects of both residential and workplace exposure to air pollution on breast cancer risk ...
Gut Microbiome Variations and Colorectal Cancer Risk
Researchers have identified significant variations in the gut microbiome of patients with precancerous colorectal lesions, suggesting a potential correlation between gut bacteria and the onset of precancerous lesions and colorectal cancer, according to new findings presented by Gacesa et al at...
The Future of AI in Cancer Care
New research has illustrated the strides being made to apply modern artificial intelligence (AI) computing methods to oncology, according to new findings to be presented at the European Society for Medical Oncology (ESMO) Congress 2023. Background Researchers have long investigated the potential of ...
FDA Approves Neoadjuvant/Adjuvant Pembrolizumab for Resectable NSCLC
On October 16, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as postsurgical adjuvant treatment, for resectable (tumors ≥ 4 cm or node-positive)...
Breast Cancer 2022–2023 Almanac
The past year has been an exciting time for breast oncologists and patients with all stages of breast cancer, with new agents approved and long-term results from pivotal trials showing improved survival for patients with metastatic disease. Let’s take a look at some of the highlights in early-stage ...
